文献速递产科母胎医学

阿司匹林延缓子痫前期的发展

Aspirin delays the development of preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2019-02-21

本研究为对阿司匹林用于循证子痫前期预防试验(ASPRE)数据的非计划探索性分析,检验阿司匹林通过延迟子痫前期孕妇分娩时间而发挥作用的假说。结果显示,在随机分组时早产子痫前期风险较低(<1/50)的组中,足月子痫前期发生率降低(比值比 0.62,95% 置信区间 0.29-1.30);模型估计,对于安慰剂组中原本在 24 周分娩者,阿司匹林可将子痫前期分娩的孕龄延迟约 4.4 周(95% 置信区间 1.4-7.1 周),且该延迟效应随孕龄每增加一周而减少约 0.23 周(95% 置信区间 0.021-0.40 周),至 40+0 周时估计延迟为 0.8 周(95% 置信区间 -0.03 至 1.7 周)。结论认为 ASPRE 试验数据与阿司匹林延迟子痫前期分娩孕龄的假说一致。

要点

  • 在早产子痫前期风险<1/50组,足月子痫前期比值比 0.62(95%置信区间 0.29-1.30)。
  • 模型估计阿司匹林可将子痫前期分娩孕龄延迟,24周时约4.4周,40+0周时约0.8周。

核心结论

  • ASPRE试验数据与阿司匹林延迟子痫前期孕妇分娩孕龄的假说一致。

研究设计与样本

  • 本研究为对阿司匹林用于循证子痫前期预防试验(ASPRE)数据的非计划探索性分析。
  • ASPRE试验中,早产子痫前期风险大于1/100的同意女性被随机分配至阿司匹林或安慰剂治疗。
  • 分析按随机分组时早产子痫前期风险以1/50为界分为较高风险(≥1/50)和较低风险(<1/50)两层。

主要发现

  • 在较低风险组(<1/50),足月子痫前期发生率降低(比值比 0.62,95%置信区间 0.29-1.30)。
  • 上述效应均未达统计学显著,但与延迟假说一致。
  • 在阿司匹林相关延迟假说框架下,对于安慰剂组中原本在24周分娩者,阿司匹林估计将子痫前期分娩孕龄延迟4.4周(95%置信区间 1.4-7.1周)。
  • 延迟效应随孕龄每增加一周估计减少0.23周(95%置信区间 0.021-0.40周),至40+0周时估计延迟为0.8周(95%置信区间 -0.03至1.7周)。

关键数值与推荐

  • ASPRE试验主要结局早产子痫前期发生率:比值比 0.38(95%置信区间 0.20-0.74)。
  • ASPRE试验次要结局足月子痫前期发生率:比值比 0.95(95%置信区间 0.64-1.39)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为非计划探索性分析。
  • 足月子痫前期在较低风险组和较高风险组的效应均未达统计学显著。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial, risks of preterm preeclampsia were obtained from the competing risk model. Consenting women with risks of greater than 1 in 100 were randomized to treatment with aspirin or placebo. The trial showed strong evidence of an effect (odds ratio, 0.38, 95% confidence interval, 0.20-0.74) on the incidence of preterm preeclampsia, which was the primary outcome of Aspirin for Evidence-Based Preeclampsia Prevention. There was a small and insignificant effect on the incidence of term preeclampsia, which was a secondary outcomes (odds ratio, 0.95, 95% confidence interval, 0.64-1.39). These differential effects on term and preterm preeclampsia could reflect a mechanism in which the action of aspirin is to delay the delivery with preeclampsia, thereby converting what would be, without treatment, preterm preeclampsia to term preeclampsia. OBJECTIVE: The objective of the study was to examine the hypothesis that the effect of aspirin is to delay the time of delivery in women who have preeclampsia. STUDY DESIGN: This was an unplanned exploratory analysis of data from the Aspirin for Evidence-Based Preeclampsia Prevention trial. The delay hypothesis predicts that in groups for which preterm preeclampsia, without aspirin, were infrequent relative to term preeclampsia, a reduction in term preeclampsia would be expected because few cases of preterm preeclampsia would be converted to term preeclampsia. In contrast, in groups for which preterm preeclampsia were frequent relative to term preeclampsia, the conversion of preterm preeclampsia to term preeclampsia by aspirin would reduce or even reverse any effect on the incidence term preeclampsia. This is examined using the Aspirin for Evidence-Based Preeclampsia Prevention trial data by analysis of the effect of aspirin on the incidence of term preeclampsia stratified according to the risk of preterm preeclampsia at randomization. Given that women were included in Aspirin for Evidence-Based Preeclampsia Prevention with risks of preterm preeclampsia >1 in 100, a risk cutoff if 1 in 50 was used to define higher risk and lower risk strata. A statistical model in which the effect of aspirin is to delay the gestational age at delivery was fitted to the Aspirin for Evidence-Based Preeclampsia Prevention trial data and the consistency of the predictions from this model with the observed incidence was demonstrated. RESULTS: In the lower-risk group (<1 in 50), there was a reduction in the incidence of term preeclampsia (odds ratio, 0.62, 95% confidence interval, 0.29-1.30). In contrast, in the higher risk group (≥1 in 50) there was a small increase in the incidence of term- preeclampsia (odds ratio 1.11, 95% confidence interval, 0.71- .75). Although these effects fail to achieve significance, they are consistent with the delay hypothesis. Within the framework of the aspirin-related delay hypothesis, the effect of aspirin was to delay the gestational age at delivery with preeclampsia by an estimated 4.4 weeks (95% confidence interval, 1.4-7.1 weeks) for those that in the placebo group would be delivered at 24 weeks and the effect decreased by an estimated 0.23 weeks (95% confidence interval, 0.021-0.40 weeks) for each week of gestation so that at 40+0 weeks, the estimated delay was by 0.8 weeks (95% confidence interval, -0.03 to 1.7 weeks). CONCLUSION: The Aspirin for Evidence-Based Preeclampsia Prevention trial data are consistent with the hypothesis that aspirin delays the gestational age at delivery with preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wright D, Nicolaides KH. Aspirin delays the development of preeclampsia. Am J Obstet Gynecol. 2019. PMID: 30797761. doi:10.1016/j.ajog.2019.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。